J. Thaddeus Beck

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

Dennis J. Slamon, Patrick Neven, Stephen Chia et al. · Journal of Clinical Oncology · 2018 · 1.1K citations

Advanced Breast Cancer, Fulvestrant V Placebo, Breast Oncology +15

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

Dennis J. Slamon, Patrick Neven, Stephen Chia et al. · New England Journal of Medicine · 2019 · 797 citations · Full text

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

Paolo A. Ascierto, Dirk Schadendorf, Carola Berking et al. · The Lancet Oncology · 2013 · 638 citations

Tumor Biology, Open-label Phase 2, Medicine +12

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer

Mary L. Disis, Matthew H. Taylor, Karen Kelly et al. · JAMA Oncology · 2019 · 417 citations · Full text

Alleviation of Systemic Manifestations of Castleman's Disease by Monoclonal Anti-Interleukin-6 Antibody

J. Thaddeus Beck, Su-Ming Hsu, John Wijdenes et al. · New England Journal of Medicine · 1994 · 332 citations · Full text

Monoclonal Anti-interleukin-6 Antibody, Immunohematology, Immunodeficiencies +22